Pursuit Vascular announces that its ClearGuard® HD Antimicrobial Barrier Cap has been selected as a finalist in the Medical Design Excellence Awards competition
MAPLE GROVE, Minn.--(BUSINESS WIRE)--Pursuit Vascular announced today that its ClearGuard HD Antimicrobial Barrier Cap has been selected as a finalist in the “Drug-Delivery Devices and Combination Products” category of the prestigious 19th Annual Medical Design Excellence Awards (MDEA) competition. Finalists were officially announced in the May issue of Medical Device and Diagnostic Industry magazine.
“We are thrilled for the ClearGuard HD Antimicrobial Barrier Cap to be recognized as a finalist in the prestigious MDEA awards program”
The prevalence of hemodialysis catheters remains high, and despite current infection control procedures results in costly and potentially deadly catheter-related bloodstream infections. The new ClearGuard HD Antimicrobial Barrier Cap is the first and only device cleared for sale in the U.S. that kills infection-causing bacteria inside a long-term hemodialysis catheter. The elegant design is simple to use yet highly effective, clinically proven to substantially reduce both bloodstream infections and hospitalizations. Feedback from nurses and technicians in outpatient dialysis clinics has been outstanding, and the intuitive design may even enable more home-based dialysis and patient self-care in the future.
The MDEA is the medical technology industry’s premier design competition, and its panel of third-party jurors are committed to searching worldwide for the highest caliber medical devices that save lives, improve patient healthcare and transform medical technology. Entries are judged by an impartial panel of experts, including practicing doctors, nurses, and technicians as well as industrial designers, engineers, manufacturers, and human factors experts.
The 2016 MDEA Juror Panel selected the ClearGuard HD Antimicrobial Barrier Cap for its design and engineering innovation; function and user-related innovation; patient benefits; business benefits; and overall benefit to the healthcare system.
“We are thrilled for the ClearGuard HD Antimicrobial Barrier Cap to be recognized as a finalist in the prestigious MDEA awards program,” said Doug Killion, President and CEO of Pursuit Vascular. “Our novel ClearGuard technology platform is playing an important role in reducing infections and keeping patients out of the hospital, which are all critical drivers as we enter an era of value-based care.”
Winners will be revealed at the 2016 MDEA Awards Ceremony being held Tuesday, June 14, 2016 in conjunction with the MD&M East event at the Jacob K. Javits Convention Center in New York City.
About the ClearGuard HD Antimicrobial Barrier Cap
The ClearGuard HD Antimicrobial Barrier Cap is the first and only device cleared for sale in the U.S. that kills infection-causing bacteria inside a long-term hemodialysis catheter; triggering the creation of new Product Code (PEH) by the Food and Drug Administration (FDA). This simple yet revolutionary single-use device is protected by five issued U.S. patents, and several other U.S. and International patent applications are pending. For more information visit www.clearguardhd.com
About Pursuit Vascular
Headquartered in Maple Grove, Minnesota, Pursuit Vascular, Inc. is developing a family of innovative single-use products designed to protect patients from acquiring life-threatening infections associated with long-term catheter and port use, while reducing the cost of healthcare. For more information visit www.pursuitvascular.com
Contacts
Pursuit Vascular, Inc.
Doug Killion, 612-424-9006
